Human Apolipoprotein C-I (Apo C1) AssayMax ELISA KitHuman Apolipoprotein C-I (Apo C1) AssayMax ELISA Kit
Move your mouse over image or click to enlarge

Human Apolipoprotein C-I (Apo C1) AssayMax ELISA Kit

This assay employs a quantitative enzyme immunoassay technique that measures the specified antigen in samples.

Cat# Size Price Qty Buy
EA8011-2 96 Well Plate £276.25

Additional Information

Property Value or Rating
Manufacturer Assaypro, LLC.
Product Type AssayMax™ ELISA Kits
Samples Serum, Cell Culture
Species Human
Reactivity Human
Assay Format Sandwich ELISA
Product Size 96 Well Plate
Range 0.031-2 ug/ml
Plex Number 1
Storage Refer to component labels for details
Entrez Gene 341
Omim 107710
UniProt P02654
UniGene Hs.110675
Special Notes For Research Use Only, Not To Be Used For Diagnostic Purposes
References * Xue A et al. (2010) Discovery of serum biomarkers for pancreatic adenocarcinoma using proteomic analysis. Br. J. Cancer 103(3):391-400 
* Cohen M et al. (2011) Serum Apolipoproteins C-I and C-III Are Reduced in Stomach Cancer Patients: Results from MALDI-Based Peptidome and Immuno-Based Clinical Assays. PLoS One 6(1): e14540 
* Hansen JB et al. (2011) The Apolipoprotein C-I Content of Very-Low-Density Lipoproteins Is Associated with Fasting Triglycerides, Postprandial Lipemia, and Carotid Atherosclerosis. J Lipids. 2011:271062 doi:10.1155/2011/271062 
* Yan LR et al. (2014) A Pro-Atherogenic HDL Profile in Coronary Heart Disease Patients: An iTRAQ Labelling-Based Proteomic Approach. PLoS One. 9(5):e98368. doi: 10.1371/journal.pone.0098368. eCollection 2014 

" title="

* Xue A et al. (2010) Discovery of serum biomarkers for pancreatic adenocarcinoma using proteomic analysis. Br. J. Cancer 103(3):391-400 
* Cohen M et al. (2011) Serum Apolipoproteins C-I and C-III Are Reduced in Stomach Cancer Patients: Results from MALDI-Based Peptidome and Immuno-Based Clinical Assays. PLoS One 6(1): e14540 
* Hansen JB et al. (2011) The Apolipoprotein C-I Content of Very-Low-Density Lipoproteins Is Associated with Fasting Triglycerides, Postprandial Lipemia, and Carotid Atherosclerosis. J Lipids. 2011:271062 doi:10.1155/2011/271062 
* Yan LR et al. (2014) A Pro-Atherogenic HDL Profile in Coronary Heart Disease Patients: An iTRAQ Labelling-Based Proteomic Approach. PLoS One. 9(5):e98368. doi: 10.1371/journal.pone.0098368. eCollection 2014 

" target="_blank">

* Xue A et al. (2010) Discovery of serum biomarkers for pancreatic adenocarcinoma using proteomic analysis. Br. J. Cancer 103(3):391-400 
* Cohen M et al. (2011) Serum Apolipoproteins C-I and C-III Are Reduced in Stomach Cancer Patients: Results from MALDI-Based Peptidome and Immuno-Based Clinical Assays. PLoS One 6(1): e14540 
* Hansen JB et al. (2011) The Apolipoprotein C-I Content of Very-Low-Density Lipoproteins Is Associated with Fasting Triglycerides, Postprandial Lipemia, and Carotid Atherosclerosis. J Lipids. 2011:271062 doi:10.1155/2011/271062 
* Yan LR et al. (2014) A Pro-Atherogenic HDL Profile in Coronary Heart Disease Patients: An iTRAQ Labelling-Based Proteomic Approach. PLoS One. 9(5):e98368. doi: 10.1371/journal.pone.0098368. eCollection 2014 

Related Documents